As of June 20, 2025, Rock Creek Pharmaceuticals Inc (RCPIQ) reports a ROE (Return on Equity) of 64.30%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Rock Creek Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Rock Creek Pharmaceuticals Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2015-12-31 | 64.30% |
| 2014-12-31 | 355.49% |
| 2013-12-31 | -470.47% |
| 2012-12-31 | -91.47% |
| 2011-12-31 | -404.51% |
This slight upward trend highlights how Rock Creek Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Rock Creek Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Rock Creek Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Rock Creek Pharmaceuticals Inc (RCPIQ) | 64.30% |
| Acacia Diversified Holdings Inc (ACCA) | 104.97% |
| Bespoke Extracts Inc (BSPK) | 85.98% |
| Notis Global Inc (NGBL) | 76.97% |
| Nexien Biopharma Inc (NXEN) | 66.19% |
| Gnomestar Craft Inc (GNOM.CN) | 53.05% |
Compared to its competitors, Rock Creek Pharmaceuticals Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.